

KDR antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI16219

Product Information

ApplicationWB, IHCPrimary AccessionP35968

Other Accession NM 002253, NP 002244

Reactivity PredictedHuman, Pig, Dog, Horse, Bovine
Human, Pig, Dog, Horse, Bovine

Host Rabbit
Clonality Polyclonal
Calculated MW 151527

Additional Information

Gene ID 3791

Alias Symbol CD309, FLK1, VEGFR, VEGFR2

Other Names Vascular endothelial growth factor receptor 2, VEGFR-2, 2.7.10.1, Fetal liver

kinase 1, FLK-1, Kinase insert domain receptor, KDR, Protein-tyrosine kinase

receptor flk-1, CD309, KDR, FLK1, VEGFR2

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-KDR antibody concentration is 1 mg/ml

in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C.

Avoid repeat freeze-thaw cycles.

Precautions KDR antibody - N-terminal region is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name KDR (HGNC:6307)

Synonyms FLK1, VEGFR2

Function Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC

and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an

important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Cellular Location

Cell junction. Endoplasmic reticulum. Cell membrane. Note=Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). {ECO:0000250, ECO:0000269 | PubMed:23529610} [Isoform 2]: Secreted.

Tissue Location

Detected in cornea (at protein level). Widely expressed.

Background


Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

References

Jin P.,et al.Arthritis Res. Ther. 10:R73-R73(2008). Albuquerque R.J.,et al.Nat. Med. 15:1023-1030(2009). Yin L.Y.,et al.Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases. Yu Y.,et al.Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. Hillier L.W.,et al.Nature 434:724-731(2005).

Images

KDR in endothelial cells in blood vessale in placenta was detected using HRP/AEC red color stain.recommended for IHC on human tissue .5-10 µg/ml





WB Suggested Anti-KDR Antibody Titration: 0.2-1 μ g/ml

ELISA Titer: 1:62500

Positive Control: Human Lung

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.